Volume 20, Number 6—June 2014
Research
Human Polyomavirus 9 Infection in Kidney Transplant Patients
Els van der Meijden
, Herman F. Wunderink, Caroline S. van der Blij-de Brouwer, Hans L. Zaaijer, Joris I. Rotmans, Jan Nico Bouwes Bavinck, and Mariet C.W. Feltkamp
, Herman F. Wunderink, Caroline S. van der Blij-de Brouwer, Hans L. Zaaijer, Joris I. Rotmans, Jan Nico Bouwes Bavinck, and Mariet C.W. Feltkamp
Table 2
Detection of human polyomavirus 9 DNA and viral loads in kidney transplant patients and blood donors, the Netherlands*
| Population | Mean time after transplantation or first sample collection, mo (range) | No. samples | No. (%) HPyV9 DNA positive | Mean viral load, copies/mL (range) |
|---|---|---|---|---|
| Transplantation patients | 101 | 21 (20.8)† | 157 (25–530)‡ | |
| Transplant type | ||||
| Kidney | 83 | 17 (20.5)† | 135 (25–530)‡ | |
| Kidney and pancreas | 18 | 4 (22.2)† | 250 (89–472)‡ | |
| No. serum samples | 541 | 27 (5.0) | 137 (25–530) | |
| Mo after transplant | ||||
| Pretransplant§ | –0.3 (–1.4 to 0) | 65 | 0 | NA |
| 0 | 0.4 (0.1–1.2) | 99 | 3 (3.0) | 203 (141–265) |
| 3 | 3.5 (2.3–5.5) | 98 | 7 (7.1) | 172 (52–530) |
| 6 | 6.5 (5.5–9.6) | 97 | 6 (6.2) | 141 (25–472) |
| 9 | 9.6 (7.6–12.6) | 80 | 5 (6.3) | 125 (45–213) |
| 12 | 12.6 (9.3–16.0) | 87 | 4 (4.6) | 80 (66–92) |
| 18 |
18.2 (16.0–21.3) |
80 |
2 (2.5) |
51 (38–63) |
| Blood donors | 87 | 0 | NA | |
| No. serum samples | 174 | 0 | NA | |
| Mo after first sample collection | ||||
| 0 | 0 | 87 | 0 | NA |
| 12 | 13.4 (9.9–18.1) | 87 | 0 | NA |
*NA, not applicable.
†Patients HPyV9 positive in the follow-up period after transplant.
‡Mean load of HPyV9 DNA–positive patients based on the first positive sample per patient.
§Pretransplant samples were retrieved from the serum sample archive at the Leiden University Medical Center Clinical Microbiology Laboratory (Leiden, the Netherlands).
Page created: March 28, 2014
Page updated: March 28, 2014
Page reviewed: March 28, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.